Enlivex Therapeutics Ltd. is a clinical-stage immunotherapy company developing Allocetra, a universal, off-the-shelf cell therapy that reprograms macrophages into their homeostatic state to rebalance the immune system without suppression. This novel macrophage modulation approach targets inflammatory diseases, including age-related knee osteoarthritis to restore mobility and quality of life, as well as conditions like sepsis and solid tumors characterized by immune hyper-responses. Allocetra engages macrophages and dendritic cells to avert cytokine storms and address chronic inflammation in multi-billion-dollar markets with significant unmet needs. The company advances multiple clinical programs, featuring a simple, scalable manufacturing process for systemic or local infusion, and a favorable safety profile observed in treated patients. In parallel, Enlivex Therapeutics Ltd. manages a treasury strategy providing exposure to prediction markets through the Rain protocol, positioning it uniquely at the intersection of biotechnology and digital assets. Founded in 2005 and headquartered in Ness Ziona, Israel, the company focuses on immunology, oncology, and infectious diseases within the biotechnology sector.